A federal appeals court has issued a ruling that restricts telemedicine access to the abortion drug mifepristone across the United States, at least on a temporary basis.

The court decision affects how patients can obtain mifepristone, which is commonly used in medication abortions during early pregnancy. The ruling specifically targets telemedicine provisions that had allowed remote prescribing of the drug.

Mifepristone is typically used as part of a two-drug protocol for medication abortion, often combined with misoprostol. The drug has been approved by federal regulators for terminating early pregnancies.

Despite the restrictions on mifepristone access through telemedicine, other medications used for pregnancy termination remain available through existing channels. Medical experts note that alternative drug protocols can be effective for ending early pregnancies.

The appeals court ruling represents the latest development in ongoing legal challenges surrounding abortion medication access since the Supreme Court's decision to overturn Roe v. Wade. The temporary nature of the restriction suggests further legal proceedings may follow.